stockrowImmunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
Follow IMNM
Alert me
Immunome, Inc. (IMNM) Return on equity
Immunome, Inc.'s return on equity over the twelve months to 30 June 2026 was −64.0%, down 11.9 percentage points from fiscal 2025 (−52.1%). Over the past ten years it has ranged from −624.2% (fiscal 2020) to 34.3% (fiscal 2019); the current reading is higher than 75% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −52.1% | 142.54 |
| FY2024 | −194.6% | (38.18) |
| FY2023 | −156.5% | (40.72) |
| FY2022 | −115.7% | (60.53) |
| FY2021 | −55.2% | 569.02 |
| FY2020 | −624.2% | (658.56) |
| FY2019 | 34.3% | 8.55 |
| FY2018 | 25.8% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. compare | 940.5% |
| AUPH Aurinia Pharmaceuticals Inc compare | 61.4% |
| ADMA ADMA Biologics Inc compare | 42.0% |
| VCEL Vericel Corporation compare | 9.44% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| CLDX Celldex Therapeutics, Inc. compare | −43.9% |
| PVLA Palvella Therapeutics, Inc. compare | −46.6% |
| IMNM Immunome, Inc. | −64.0% |
| VERA Vera Therapeutics, Inc. compare | −91.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on IMNM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement